Clinical trial
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-6624 in Adult Subjects With Idiopathic Pulmonary Fibrosis
NCT01362231 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-6624 in Adult Subjects With Idiopathic Pulmonary Fibrosis
- Lead sponsor
- Gilead Sciences
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- December 31, 2010
- Completion date
- December 31, 2012
- Enrollment
- 48 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.